Cargando…

2645. Severe Human Parainfluenza Virus-associated Pneumonia in Adults, Seoul, South Korea, 2010-2019

BACKGROUND: Human parainfluenza virus (HPIV) is a major cause of acute respiratory tract infections such as croup in children and pneumonia in immunocompromised patients. HPIV infections are generally regarded as mild and self-limiting in adults, however, HPIV-associated pneumonia is increasingly re...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Joung Ha, Hong, Sang-Bum, Huh, Jin Won, Jung, Jiwon, Kim, Min Jae, Chong, Yong Pil, Sung, Heungsup, Doh, Kyung Hyun, Kim, Sung-Han, Lee, Sang-Oh, Kim, Yang Soo, Lim, Chae-Man, Koh, Younsuck, Choi, Sang-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677876/
http://dx.doi.org/10.1093/ofid/ofad500.2257
Descripción
Sumario:BACKGROUND: Human parainfluenza virus (HPIV) is a major cause of acute respiratory tract infections such as croup in children and pneumonia in immunocompromised patients. HPIV infections are generally regarded as mild and self-limiting in adults, however, HPIV-associated pneumonia is increasingly reported in adults. To the best of our knowledge, data on the epidemiological and clinical characteristics of severe HPIV-associated pneumonia in adults are limited. Therefore, we investigated the epidemiological and clinical characteristics and outcomes of severe HPIV-associated pneumonia over ten years in a large cohort of critically ill adults with severe pneumonia requiring intensive care. METHODS: This sutdy was performed as a part of a prospective observational cohort study regarding severe virus-associated pneumonia at the 28-bed medical intensive care unit (ICU) at a 2,700-bed hospital, in Seoul, South Korea. Patients with severe HPIV-associated pneumonia were enrolled in this study, and the clinical data of these patients were analyzed. To describe the clinical outcomes of severe HPIV-associated pneumonia, we compared the HPIV-associated pneumonia outcomes with those of severe influenza virus-associated pneumonia. RESULTS: A total of 143 adult patients with severe HPIV-associated pneumonia were identified. HPIV is the most common cause (25.2%) of severe viral hospital-acquired pneumonia (HAP), and it is the third most common cause (15.7%) of severe viral community-acquired pneumonia. The median age of the patients was 61.6 years old. Almost patients (97.2%) had comorbidities, and hematologic malignancy (35.0%), diabetes mellitus (23.8%), and structural lung disease (21.0%) were common cormobidities. About half of the patients (54.5%) had co-infections at the time of ICU admission. The 90-day mortality was comparable with that of severe influenza virus-associated pneumonia (55.2% vs 48.4%, p = 0.22). The use of ribavirin was not associated with lower mortality. Fungal co-infections were associated with higher mortality (82.4% [14/17]). [Figure: see text] [Figure: see text] CONCLUSION: In conclusion, HPIV was the leading cause of severe viral HAP with substantial mortality, comparable to that of influenza virus-associated penumonia. Fungal co-infections contributed to the high mortality rates. DISCLOSURES: All Authors: No reported disclosures